These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38128204)

  • 1. Exploring the plasticity of the InhA substrate-binding site using new diaryl ether inhibitors.
    Tamhaev R; Grosjean E; Ahamed H; Chebaiki M; Rodriguez F; Recchia D; Degiacomi G; Pasca MR; Maveyraud L; Mourey L; Lherbet C
    Bioorg Chem; 2024 Feb; 143():107032. PubMed ID: 38128204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of new diaryl ether inhibitors against Mycobacterium tuberculosis targeting the minor portal of InhA.
    Chebaiki M; Delfourne E; Tamhaev R; Danoun S; Rodriguez F; Hoffmann P; Grosjean E; Goncalves F; Azéma-Despeyroux J; Pál A; Korduláková J; Preuilh N; Britton S; Constant P; Marrakchi H; Maveyraud L; Mourey L; Lherbet C
    Eur J Med Chem; 2023 Nov; 259():115646. PubMed ID: 37482022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
    Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
    J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel diaryl ether derivatives as InhA inhibitors: Design, synthesis and antimycobacterial activity.
    Abdelaziz OA; Othman DIA; Abdel-Aziz MM; Badr SMI; Eisa HM
    Bioorg Chem; 2022 Dec; 129():106125. PubMed ID: 36126606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
    Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
    J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
    Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
    Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-dependent diaryl ether inhibitors of InhA: structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy.
    Pan P; Knudson SE; Bommineni GR; Li HJ; Lai CT; Liu N; Garcia-Diaz M; Simmerling C; Patil SS; Slayden RA; Tonge PJ
    ChemMedChem; 2014 Apr; 9(4):776-91. PubMed ID: 24616444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
    Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
    ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors.
    Ibrahim TS; Taher ES; Samir E; M Malebari A; Khayyat AN; Mohamed MFA; Bokhtia RM; AlAwadh MA; Seliem IA; Asfour HZ; Alhakamy NA; Panda SS; Al-Mahmoudy AMM
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32650556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of InhA inhibitors in the class of diphenyl ether derivatives as potential anti-tubercular agents using molecular dynamics simulations.
    Kamsri P; Koohatammakun N; Srisupan A; Meewong P; Punkvang A; Saparpakorn P; Hannongbua S; Wolschann P; Prueksaaroon S; Leartsakulpanich U; Pungpo P
    SAR QSAR Environ Res; 2014; 25(6):473-88. PubMed ID: 24785640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
    Guardia A; Gulten G; Fernandez R; Gómez J; Wang F; Convery M; Blanco D; Martínez M; Pérez-Herrán E; Alonso M; Ortega F; Rullás J; Calvo D; Mata L; Young R; Sacchettini JC; Mendoza-Losana A; Remuiñán M; Ballell Pages L; Castro-Pichel J
    ChemMedChem; 2016 Apr; 11(7):687-701. PubMed ID: 26934341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.
    Stigliani JL; Bernardes-Génisson V; Bernadou J; Pratviel G
    Org Biomol Chem; 2012 Aug; 10(31):6341-9. PubMed ID: 22751934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment-Based Design of
    Sabbah M; Mendes V; Vistal RG; Dias DMG; Záhorszká M; Mikušová K; Korduláková J; Coyne AG; Blundell TL; Abell C
    J Med Chem; 2020 May; 63(9):4749-4761. PubMed ID: 32240584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography.
    Kamsri P; Hanwarinroj C; Phusi N; Pornprom T; Chayajarus K; Punkvang A; Suttipanta N; Srimanote P; Suttisintong K; Songsiriritthigul C; Saparpakorn P; Hannongbua S; Rattanabunyong S; Seetaha S; Choowongkomon K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Chen Z; Zhu W; Blood RA; Takebayashi Y; Hinchliffe P; Mulholland AJ; Spencer J; Pungpo P
    J Chem Inf Model; 2020 Jan; 60(1):226-234. PubMed ID: 31820972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
    Saharan VD; Mahajan SS
    Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First triclosan-based macrocyclic inhibitors of InhA enzyme.
    Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
    Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study.
    da Costa AL; Pauli I; Dorn M; Schroeder EK; Zhan CG; de Souza ON
    J Mol Model; 2012 May; 18(5):1779-90. PubMed ID: 21833828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel and potent InhA direct inhibitors by ensemble docking-based virtual screening and biological assays.
    Zhang Q; Han J; Zhu Y; Yu F; Hu X; Tong HHY; Liu H
    J Comput Aided Mol Des; 2023 Dec; 37(12):695-706. PubMed ID: 37642861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
    Rawat R; Whitty A; Tonge PJ
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.